Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Carigent Therapeutics Awarded NCI Phase I SBIR Grant for Preclinical Development of Targeted, Long-Circulating Nanoparticle Therapeutic to Treat Non-H

Abstract:
Carigent Therapeutics, Inc., announced today that the National Cancer Institute of the National Institutes of Health has awarded Carigent a one-year, $153,000 Phase I Small Business Innovation Research (SBIR) grant to advance preclinical development of an innovative, long-circulating nanoparticle therapeutic that targets the specific molecular lesions in non-Hodgkin's lymphoma (NHL) patients.

Carigent Therapeutics Awarded NCI Phase I SBIR Grant for Preclinical Development of Targeted, Long-Circulating Nanoparticle Therapeutic to Treat Non-H

New Haven, CT | Posted on January 16th, 2008

Carigent's novel therapeutic approach is based on the company's proprietary technology for engineering biodegradable nanoparticles with exceptionally high-density surface modifications. The platform enables Carigent to design customized, multifunctional nanoscale carriers with the unique combined capability of:
Tethering multiple "functional groups" such as targeting ligands, diagnostic imaging agents, and polyethylene glycol (PEG) to the nanoparticle surface at previously unattainable densities, and Encapsulating single or combined therapeutic and/or diagnostic agents inside the nanoparticle for sustained, controlled release directly into targeted (i.e., diseased) tissues and cells.

"Non-Hodgkin's lymphoma has one of the fastest-growing incidence rates among cancers and is now the sixth most common cancer in the U.S.," said Seth Feuerstein, MD, JD, President and a co-founder of Carigent. "As we accelerate development of Carigent's engineered nanoparticle therapeutics to address unmet needs in cancer treatment, we are grateful for this financial support from the National Cancer Institute and the additional validation it provides Carigent's versatile nanoparticle delivery technology. The ability to modify particles for targeting as well as increased circulation time is what makes this an exciting project for the field."

####

About Carigent Therapeutics, Inc.
Carigent Therapeutics, Inc. is a biotechnology company developing and commercializing safer and more effective therapeutic and diagnostic products based on the companyís platform technology: Nanoparticles that enable delivery and controlled release of therapeutic and diagnostic agents into specific locations within the body and tissues. The companyís products and services are based on novel nanotechnology developed at Yale University that provides the unique capability of tethering agents for targeting, imaging, and increased circulation time at unprecedented densities to the surface of biodegradable polymer nanoparticles, resulting in drugs that bind to their targets more effectively, are delivered at a higher concentration to the desired location, and/or remain in the bloodstream longer than other nanotechnology-based drugs. The Carigent technology is broadly applicable across a wide variety of disease states and supports multiple types of targeting strategies and carrier designs for existing drugs as well as new drugs in development. Carigentís initial product development programs are focused on cancer therapeutics. In parallel, Carigent provides access to its nanoparticle drug delivery technology through collaborations and partnerships with pharmaceutical, biotechnology, and diagnostics companies. Carigent was established in 2007 and is based in New Haven, Connecticut.

For more information, please click here

Contacts:
Mary Moynihan
M2Friend Biocommunications
(802) 951-9600

Copyright © Carigent Therapeutics, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Cryo-electron microscopy achieves unprecedented resolution using new computational methods March 25th, 2017

Argon is not the 'dope' for metallic hydrogen March 24th, 2017

Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017

Artificial photosynthesis steps into the light: Rice University lab turns transition metals into practical catalyst for solar, other applications March 23rd, 2017

Govt.-Legislation/Regulation/Funding/Policy

Cryo-electron microscopy achieves unprecedented resolution using new computational methods March 25th, 2017

Argon is not the 'dope' for metallic hydrogen March 24th, 2017

Nanobiotix: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma March 23rd, 2017

Rice U. refines filters for greener natural gas: New study defines best materials for carbon capture, methane selectivity March 23rd, 2017

Nanomedicine

Cryo-electron microscopy achieves unprecedented resolution using new computational methods March 25th, 2017

Nanobiotix: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma March 23rd, 2017

Nanoparticle paves the way for new triple negative breast cancer drug March 20th, 2017

Block copolymer micellization as a protection strategy for DNA origami March 17th, 2017

Announcements

Cryo-electron microscopy achieves unprecedented resolution using new computational methods March 25th, 2017

Argon is not the 'dope' for metallic hydrogen March 24th, 2017

Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017

Artificial photosynthesis steps into the light: Rice University lab turns transition metals into practical catalyst for solar, other applications March 23rd, 2017

Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records

Argon is not the 'dope' for metallic hydrogen March 24th, 2017

Rice U. refines filters for greener natural gas: New study defines best materials for carbon capture, methane selectivity March 23rd, 2017

Artificial photosynthesis steps into the light: Rice University lab turns transition metals into practical catalyst for solar, other applications March 23rd, 2017

Scientists discover new 'boat' form of promising semiconductor: GeSe Uncommon form attenuates semiconductor's band gap size March 23rd, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project